{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:01:08Z","timestamp":1784890868284,"version":"3.55.0"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Menopause is a neuroendocrine process with important implications for neurological health. This review examines the complex, multidirectional relationships between menopause and major central nervous system conditions, including stroke, migraine, epilepsy, multiple sclerosis, Parkinson\u2019s disease, and Alzheimer\u2019s disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Menopause may mark an inflection point for vascular injury, neurodegeneration, and disability accumulation in several neurological conditions. Perimenopausal hormonal fluctuations may exacerbate migraines and seizures in susceptible women. Research increasingly supports the critical window hypothesis for estrogen therapy and highlights the importance of distinguishing reproductive and chronological aging when interpreting neurologic trajectories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Menopause represents an important transition for many conditions. Hormone therapy has heterogenous effects with cognitive benefit in premature ovarian insufficiency, harm related to stroke risk in older women, and greater uncertainty in other conditions. Therefore, individualized risk-benefit assessment is essential. Research gaps remain significant, and menopause should be a priority area for neurologic research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11910-026-01506-1","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:40:04Z","timestamp":1784882404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Neurology of Menopause"],"prefix":"10.1007","volume":"26","author":[{"given":"Hannah J.","family":"Roeder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique C.","family":"Leira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"1506_CR1","unstructured":"Organization WH. Menopause. 2024 [cited 2026; Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/menopause"},{"issue":"4","key":"1506_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/gme.0b013e31824d8f40","volume":"19","author":"SD Harlow","year":"2012","unstructured":"Harlow SD, et al. Executive summary of the Stages of Reproductive Aging Workshop\u2009+\u200910: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387\u201395.","journal-title":"Menopause"},{"key":"1506_CR3","unstructured":"Xu J, et al. Mortality in the United States, 2024, in NCHS Data Briefs [Internet]. National Center for Health Statistics (US); 2026."},{"issue":"4","key":"1506_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1161\/CIRCRESAHA.121.319915","volume":"130","author":"KM Rexrode","year":"2022","unstructured":"Rexrode KM, et al. The impact of sex and gender on stroke. Circul Res. 2022;130(4):512\u201328.","journal-title":"Circul Res"},{"issue":"1","key":"1506_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S1474-4422(11)70269-1","volume":"11","author":"L Lisabeth","year":"2012","unstructured":"Lisabeth L, Bushnell C. Stroke risk in women: the role of menopause and hormone therapy. Lancet Neurol. 2012;11(1):82\u201391.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1506_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1161\/STROKEAHA.120.032898","volume":"52","author":"MV Vyas","year":"2021","unstructured":"Vyas MV, et al. Stroke incidence by sex across the lifespan. Stroke. 2021;52(2):447\u201351.","journal-title":"Stroke"},{"issue":"4","key":"1506_CR7","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1161\/STROKEAHA.120.028910","volume":"51","author":"TE Madsen","year":"2020","unstructured":"Madsen TE, et al. Temporal trends in stroke incidence over time by sex and age in the GCNKSS. Stroke. 2020;51(4):1070\u20136.","journal-title":"Stroke"},{"issue":"2","key":"1506_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jamaneurol.2018.3862","volume":"76","author":"VJ Howard","year":"2019","unstructured":"Howard VJ, et al. Sex and race differences in the association of incident ischemic stroke with risk factors. JAMA Neurol. 2019;76(2):179\u201386.","journal-title":"JAMA Neurol"},{"issue":"6","key":"1506_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S2213-8587(22)00076-6","volume":"10","author":"RE Nappi","year":"2022","unstructured":"Nappi RE, et al. Menopause: a cardiometabolic transition. Lancet Diabetes Endocrinol. 2022;10(6):442\u201356.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"1506_CR10","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1210\/jc.2012-2244","volume":"97","author":"KL Moreau","year":"2012","unstructured":"Moreau KL, et al. Endothelial function is impaired across the stages of the menopause transition in healthy women. J Clin Endocrinol Metab. 2012;97(12):4692\u2013700.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1506_CR11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1161\/CIRCRESAHA.121.319424","volume":"130","author":"S Samargandy","year":"2022","unstructured":"Samargandy S, et al. Trajectories of Blood Pressure in Midlife Women: Does Menopause Matter? Circ Res. 2022;130(3):312\u201322.","journal-title":"Circ Res"},{"issue":"11","key":"1506_CR12","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/aje\/kwp043","volume":"169","author":"CA Derby","year":"2009","unstructured":"Derby CA, et al. Lipid changes during the menopause transition in relation to age and weight: the Study of Women\u2019s Health Across the Nation. Am J Epidemiol. 2009;169(11):1352\u201361.","journal-title":"Am J Epidemiol"},{"issue":"17","key":"1506_CR13","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa010534","volume":"345","author":"CM Viscoli","year":"2001","unstructured":"Viscoli CM, et al. A Clinical Trial of Estrogen-Replacement Therapy after Ischemic Stroke. N Engl J Med. 2001;345(17):1243\u20139.","journal-title":"N Engl J Med"},{"issue":"7","key":"1506_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/jama.280.7.605","volume":"280","author":"S Hulley","year":"1998","unstructured":"Hulley S, et al. Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. JAMA. 1998;280(7):605\u201313.","journal-title":"JAMA"},{"issue":"3","key":"1506_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"WG Investigators","year":"2002","unstructured":"Investigators WG. f.t.W.s.H.I., Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal WomenPrincipal Results From the Women\u2019s Health Initiative Randomized Controlled Trial. JAMA. 2002;288(3):321\u201333.","journal-title":"JAMA"},{"key":"1506_CR16","doi-asserted-by":"crossref","unstructured":"Yang L, Toriola AT. Menopausal hormone therapy use among postmenopausal women. JAMA Health Forum. American Medical Association; 2024.","DOI":"10.1001\/jamahealthforum.2024.3128"},{"issue":"11","key":"1506_CR17","doi-asserted-by":"publisher","first-page":"e1002445","DOI":"10.1371\/journal.pmed.1002445","volume":"14","author":"GD Carrasquilla","year":"2017","unstructured":"Carrasquilla GD, et al. Postmenopausal hormone therapy and risk of stroke: A pooled analysis of data from population-based cohort studies. PLoS Med. 2017;14(11):e1002445.","journal-title":"PLoS Med"},{"issue":"6","key":"1506_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2174\/1570159X18666200123165652","volume":"18","author":"H Guo","year":"2020","unstructured":"Guo H, et al. The critical period for neuroprotection by estrogen replacement therapy and the potential underlying mechanisms. Curr Neuropharmacol. 2020;18(6):485\u2013500.","journal-title":"Curr Neuropharmacol"},{"issue":"8","key":"1506_CR19","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1161\/STROKEAHA.117.017132","volume":"48","author":"E L\u00f8kkegaard","year":"2017","unstructured":"L\u00f8kkegaard E, Nielsen LH, Keiding N. Risk of Stroke With Various Types of Menopausal Hormone Therapies. Stroke. 2017;48(8):2266\u20139.","journal-title":"Stroke"},{"issue":"10","key":"1506_CR20","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1161\/STROKEAHA.125.050986","volume":"56","author":"KG Haddadan","year":"2025","unstructured":"Haddadan KG, et al. Recurrent ischemic stroke and vaginal estradiol in women with prior ischemic stroke: A nationwide nested case-control study. Stroke. 2025;56(10):2888\u201394.","journal-title":"Stroke"},{"issue":"12","key":"1506_CR21","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000475","volume":"55","author":"C Bushnell","year":"2024","unstructured":"Bushnell C, et al. 2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association\/American Stroke Association. Stroke. 2024;55(12):e344\u2013424.","journal-title":"Stroke"},{"key":"1506_CR22","doi-asserted-by":"crossref","unstructured":"The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause, 2023. 30(6): pp. 573\u201390.","DOI":"10.1097\/GME.0000000000002200"},{"issue":"5","key":"1506_CR23","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.3390\/jcm14051438","volume":"14","author":"B Meczekalski","year":"2025","unstructured":"Meczekalski B, et al. A new hope for woman with vasomotor symptoms: neurokinin B antagonists. J Clin Med. 2025;14(5):1438.","journal-title":"J Clin Med"},{"issue":"4","key":"1506_CR24","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1161\/STROKEAHA.108.542993","volume":"40","author":"LD Lisabeth","year":"2009","unstructured":"Lisabeth LD, et al. Age at Natural Menopause and Risk of Ischemic Stroke. Stroke. 2009;40(4):1044\u20139.","journal-title":"Stroke"},{"issue":"18","key":"1506_CR25","doi-asserted-by":"publisher","first-page":"e030280","DOI":"10.1161\/JAHA.123.030280","volume":"12","author":"L Tschiderer","year":"2023","unstructured":"Tschiderer L, et al. Age at menopause and the risk of stroke: observational and Mendelian randomization analysis in 204 244 postmenopausal women. J Am Heart Association. 2023;12(18):e030280.","journal-title":"J Am Heart Association"},{"issue":"8","key":"1506_CR26","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1161\/STROKEAHA.120.030558","volume":"52","author":"SJ Welten","year":"2021","unstructured":"Welten SJ, et al. Age at menopause and risk of ischemic and hemorrhagic stroke. Stroke. 2021;52(8):2583\u201391.","journal-title":"Stroke"},{"issue":"3","key":"1506_CR27","doi-asserted-by":"publisher","first-page":"e017416","DOI":"10.1161\/JAHA.120.017416","volume":"10","author":"RC Thurston","year":"2021","unstructured":"Thurston RC, et al. Menopausal vasomotor symptoms and risk of incident cardiovascular disease events in SWAN. J Am Heart Association. 2021;10(3):e017416.","journal-title":"J Am Heart Association"},{"issue":"6","key":"1506_CR28","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.ajog.2020.06.039","volume":"223","author":"D Zhu","year":"2020","unstructured":"Zhu D, et al. Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies. Am J Obstet Gynecol. 2020;223(6):898. e1-898. e16.","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"1506_CR29","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1111\/head.12150","volume":"53","author":"DC Buse","year":"2013","unstructured":"Buse DC, et al. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe H eadache: results of the A merican migraine prevalence and prevention (AMPP) study. Headache: J Head Face Pain. 2013;53(8):1278\u201399.","journal-title":"Headache: J Head Face Pain"},{"issue":"1","key":"1506_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/head.12482","volume":"55","author":"RC Burch","year":"2015","unstructured":"Burch RC, et al. The prevalence and burden of migraine and severe headache in the U nited S tates: updated statistics from government health surveillance studies. Headache: J Head Face Pain. 2015;55(1):21\u201334.","journal-title":"Headache: J Head Face Pain"},{"issue":"1","key":"1506_CR31","first-page":"1","volume":"38","author":"HC Society","year":"2018","unstructured":"Society HC. C.o.t.I.H., The international classification of headache disorders. Cephalalgia. 2018;38(1):1.","journal-title":"Cephalalgia"},{"issue":"4","key":"1506_CR32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1212\/WNL.22.4.355","volume":"22","author":"BW Somerville","year":"1972","unstructured":"Somerville BW. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology. 1972;22(4):355\u2013355.","journal-title":"Neurology"},{"issue":"2","key":"1506_CR33","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/head.12763","volume":"56","author":"VT Martin","year":"2016","unstructured":"Martin VT, et al. Perimenopause and Menopause Are Associated With High Frequency Headache in Women With Migraine: Results of the American Migraine Prevalence and Prevention Study. Headache. 2016;56(2):292\u2013305.","journal-title":"Headache"},{"issue":"4","key":"1506_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.yfrne.2013.06.001","volume":"34","author":"\u00c5 Amandusson","year":"2013","unstructured":"Amandusson \u00c5, Blomqvist A. Estrogenic influences in pain processing. Front Neuroendocr. 2013;34(4):329\u201349.","journal-title":"Front Neuroendocr"},{"issue":"3","key":"1506_CR35","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1177\/0333102417739584","volume":"39","author":"A Labastida-Ram\u00edrez","year":"2019","unstructured":"Labastida-Ram\u00edrez A, et al. Gender aspects of CGRP in migraine. Cephalalgia. 2019;39(3):435\u201344.","journal-title":"Cephalalgia"},{"issue":"11","key":"1506_CR36","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1007\/s00221-020-05923-7","volume":"238","author":"A Cetinkaya","year":"2020","unstructured":"Cetinkaya A, et al. Effects of estrogen and progesterone on the neurogenic inflammatory neuropeptides: implications for gender differences in migraine. Exp Brain Res. 2020;238(11):2625\u201339.","journal-title":"Exp Brain Res"},{"issue":"10","key":"1506_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41582-021-00544-2","volume":"17","author":"DN Krause","year":"2021","unstructured":"Krause DN, et al. Hormonal influences in migraine \u2014 interactions of oestrogen, oxytocin and CGRP. Nat Reviews Neurol. 2021;17(10):621\u201333.","journal-title":"Nat Reviews Neurol"},{"key":"1506_CR38","doi-asserted-by":"crossref","unstructured":"Ripa P et al. Migraine in menopausal women: a systematic review. Int J women\u2019s health, 2015: pp. 773\u201382.","DOI":"10.2147\/IJWH.S70073"},{"key":"1506_CR39","doi-asserted-by":"publisher","first-page":"108657","DOI":"10.1016\/j.maturitas.2025.108657","volume":"200","author":"SE Mannion","year":"2025","unstructured":"Mannion SE, et al. Incidence of de novo migraine after premenopausal bilateral oophorectomy. Maturitas. 2025;200:108657.","journal-title":"Maturitas"},{"key":"1506_CR40","doi-asserted-by":"crossref","unstructured":"Faubion SS et al. Are Migraine and Vasomotor Symptoms Linked? in Mayo Clinic proceedings. 2023.","DOI":"10.1016\/j.mayocp.2023.01.010"},{"issue":"1","key":"1506_CR41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s10194-025-02083-3","volume":"26","author":"NS Bugge","year":"2025","unstructured":"Bugge NS, et al. Migraine through puberty and menopausal transition-data from the population-based Norwegian Women and Health study (NOWAC). J Headache Pain. 2025;26(1):145.","journal-title":"J Headache Pain"},{"issue":"2","key":"1506_CR42","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1526-4610.2006.00343.x","volume":"46","author":"KM Martins","year":"2006","unstructured":"Martins KM, et al. Migraine in the elderly: a comparison with migraine in young adults. Headache: J Head Face Pain. 2006;46(2):312\u20136.","journal-title":"Headache: J Head Face Pain"},{"issue":"4","key":"1506_CR43","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/head.13247","volume":"58","author":"P de Rijk","year":"2018","unstructured":"de Rijk P, Resseguier N, Donnet A. Headache characteristics and clinical features of elderly migraine patients. Headache: J Head Face Pain. 2018;58(4):525\u201333.","journal-title":"Headache: J Head Face Pain"},{"key":"1506_CR44","doi-asserted-by":"crossref","unstructured":"Korn TF, Bernstein C. Migraine across the menopausal transition and beyond: A narrative review. Headache, 2026.","DOI":"10.1111\/head.70071"},{"issue":"2","key":"1506_CR45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0378-5122(00)00215-2","volume":"38","author":"RE Nappi","year":"2001","unstructured":"Nappi RE, et al. Course of primary headaches during hormone replacement therapy. Maturitas. 2001;38(2):157\u201363.","journal-title":"Maturitas"},{"issue":"Suppl 1","key":"1506_CR46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10072-015-2155-8","volume":"36","author":"G Allais","year":"2015","unstructured":"Allais G, et al. Migraine in perimenopausal women. Neurol Sci. 2015;36(Suppl 1):79\u201383.","journal-title":"Neurol Sci"},{"issue":"3","key":"1506_CR47","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1080\/13697137.2018.1439914","volume":"21","author":"M Hipolito Rodrigues","year":"2018","unstructured":"Hipolito Rodrigues M, et al. Migraine, hormones and the menopausal transition. Climacteric. 2018;21(3):256\u201366.","journal-title":"Climacteric"},{"issue":"7","key":"1506_CR48","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/GME.0000000000002028","volume":"29","author":"SS Faubion","year":"2022","unstructured":"Faubion SS, et al. The 2022 hormone therapy position statement of the North American Menopause Society. Menopause. 2022;29(7):767\u201394.","journal-title":"Menopause"},{"issue":"3","key":"1506_CR49","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/pm\/pnad141","volume":"25","author":"A Gonzalez-Martinez","year":"2024","unstructured":"Gonzalez-Martinez A, et al. Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study. Pain Med. 2024;25(3):194\u2013202.","journal-title":"Pain Med"},{"issue":"1","key":"1506_CR50","first-page":"e200373","volume":"15","author":"A Salim","year":"2025","unstructured":"Salim A, et al. Efficacy and tolerability of anti-CGRP monoclonal antibodies in patients aged\u2009\u2265\u200965 years with daily or nondaily migraine. Neurology: Clin Pract. 2025;15(1):e200373.","journal-title":"Neurology: Clin Pract"},{"issue":"1","key":"1506_CR51","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s10194-023-01585-2","volume":"24","author":"A Mu\u00f1oz-Vendrell","year":"2023","unstructured":"Mu\u00f1oz-Vendrell A, et al. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients. J Headache Pain. 2023;24(1):63.","journal-title":"J Headache Pain"},{"issue":"2","key":"1506_CR52","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1001\/jamaneurol.2024.4537","volume":"82","author":"S Yang","year":"2025","unstructured":"Yang S, et al. Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine. JAMA Neurol. 2025;82(2):132\u201341.","journal-title":"JAMA Neurol"},{"issue":"10","key":"1506_CR53","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/j.1528-1157.1999.tb02012.x","volume":"40","author":"CL Harden","year":"1999","unstructured":"Harden CL, et al. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia. 1999;40(10):1402\u20137.","journal-title":"Epilepsia"},{"issue":"4 Pt 1","key":"1506_CR54","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/gme.0b013e318174ea4d","volume":"15","author":"HG Burger","year":"2008","unstructured":"Burger HG, et al. Cycle and hormone changes during perimenopause: the key role of ovarian function. Menopause. 2008;15(4 Pt 1):603\u201312.","journal-title":"Menopause"},{"issue":"1","key":"1506_CR55","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S1474-4422(12)70239-9","volume":"12","author":"CL Harden","year":"2013","unstructured":"Harden CL, Pennell PB. Neuroendocrine considerations in the treatment of men and women with epilepsy. Lancet Neurol. 2013;12(1):72\u201383.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1506_CR56","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1528-1157.1999.tb02076.x","volume":"40","author":"F Abbasi","year":"1999","unstructured":"Abbasi F, et al. Effects of menopause on seizures in women with epilepsy. Epilepsia. 1999;40(2):205\u201310.","journal-title":"Epilepsia"},{"key":"1506_CR57","unstructured":"Tettenborn B et al. Women with epilepsy: Evidence-based counseling across the lifespan. Epilepsia. n\/a(n\/a)."},{"issue":"12","key":"1506_CR58","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1046\/j.1528-1157.2001.13701r.x","volume":"42","author":"P Klein","year":"2001","unstructured":"Klein P, Serje A, Pezzullo JC. Premature ovarian failure in women with epilepsy. Epilepsia. 2001;42(12):1584\u20139.","journal-title":"Epilepsia"},{"issue":"4","key":"1506_CR59","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1212\/01.WNL.0000081228.48016.44","volume":"61","author":"C Harden","year":"2003","unstructured":"Harden C, et al. Seizure frequency is associated with age at menopause in women with epilepsy. Neurology. 2003;61(4):451\u20135.","journal-title":"Neurology"},{"key":"1506_CR60","doi-asserted-by":"publisher","first-page":"1658284","DOI":"10.3389\/fneur.2025.1658284","volume":"16","author":"D Kobylarek","year":"2025","unstructured":"Kobylarek D, et al. The neuroendocrine puzzle of epilepsy and infertility: what are we missing? Front Neurol. 2025;16:1658284.","journal-title":"Front Neurol"},{"key":"1506_CR61","doi-asserted-by":"publisher","first-page":"101084","DOI":"10.1016\/j.yfrne.2023.101084","volume":"71","author":"CA Cutia","year":"2023","unstructured":"Cutia CA, Christian-Hinman CA. Mechanisms linking neurological disorders with reproductive endocrine dysfunction: Insights from epilepsy research. Front Neuroendocrinol. 2023;71:101084.","journal-title":"Front Neuroendocrinol"},{"issue":"66suppl3","key":"1506_CR62","first-page":"S23","volume":"66","author":"AG Herzog","year":"2006","unstructured":"Herzog AG. Menstrual disorders in women with epilepsy. Neurology. 2006;66(66suppl3):S23\u20138.","journal-title":"Neurology"},{"issue":"9","key":"1506_CR63","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1111\/ene.15916","volume":"30","author":"V Carvalho","year":"2023","unstructured":"Carvalho V, et al. Sex steroid hormones and epilepsy: Effects of hormonal replacement therapy on seizure frequency of postmenopausal women with epilepsy-A systematic review. Eur J Neurol. 2023;30(9):2884\u201398.","journal-title":"Eur J Neurol"},{"issue":"9","key":"1506_CR64","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1111\/j.1528-1167.2006.00507.x","volume":"47","author":"CL Harden","year":"2006","unstructured":"Harden CL, et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia. 2006;47(9):1447\u201351.","journal-title":"Epilepsia"},{"issue":"1\u20132","key":"1506_CR65","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jns.2013.05.005","volume":"331","author":"K Beerhorst","year":"2013","unstructured":"Beerhorst K, et al. Bone disease during chronic antiepileptic drug therapy: general versus specific risk factors. J Neurol Sci. 2013;331(1\u20132):19\u201325.","journal-title":"J Neurol Sci"},{"issue":"1","key":"1506_CR66","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.seizure.2012.10.002","volume":"22","author":"JM Nicholas","year":"2013","unstructured":"Nicholas JM, et al. Fracture risk with use of liver enzyme inducing antiepileptic drugs in people with active epilepsy: cohort study using the general practice research database. Seizure. 2013;22(1):37\u201342.","journal-title":"Seizure"},{"issue":"8","key":"1506_CR67","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jamaneurol.2023.1580","volume":"80","author":"CB Josephson","year":"2023","unstructured":"Josephson CB, et al. Independent Associations of Incident Epilepsy and Enzyme-Inducing and Non\u2013Enzyme-Inducing Antiseizure Medications With the Development of Osteoporosis. JAMA Neurol. 2023;80(8):843\u201350.","journal-title":"JAMA Neurol"},{"key":"1506_CR68","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.seizure.2017.03.013","volume":"48","author":"DA Pitetzis","year":"2017","unstructured":"Pitetzis DA, et al. The effect of VPA on bone: From clinical studies to cell cultures\u2014The molecular mechanisms revisited. Seizure. 2017;48:36\u201343.","journal-title":"Seizure"},{"issue":"1","key":"1506_CR69","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40263-024-01137-5","volume":"39","author":"Y Novitskaya","year":"2025","unstructured":"Novitskaya Y, et al. Effects of one-year anti-seizure treatment with add-on cenobamate on bone density and bone turnover in adults with drug-resistant focal epilepsy: an observational study. CNS Drugs. 2025;39(1):95\u2013106.","journal-title":"CNS Drugs"},{"key":"1506_CR70","doi-asserted-by":"crossref","unstructured":"Gou C, Zhao Q, Han Y. Evaluation of bone safety and antiseizure medications: a multi-source pharmacovigilance and Mendelian randomization analysis. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology; 2026.","DOI":"10.1007\/s00210-026-04979-6"},{"key":"1506_CR71","doi-asserted-by":"publisher","first-page":"115671","DOI":"10.1016\/j.fct.2025.115671","volume":"204","author":"B Dilber","year":"2025","unstructured":"Dilber B, et al. Effect of antiseizure drugs on growing bone in prepubertal non-epileptic rats. Food Chem Toxicol. 2025;204:115671.","journal-title":"Food Chem Toxicol"},{"issue":"6","key":"1506_CR72","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1001\/jama.2024.27154","volume":"333","author":"UPST Force","year":"2025","unstructured":"Force UPST, et al. Screening for osteoporosis to prevent fractures: US preventive services task force recommendation statement. JAMA. 2025;333(6):498\u2013508.","journal-title":"JAMA"},{"key":"1506_CR73","unstructured":"Pinkerton JV. Osteoporosis Prevention, Screening, and Diagnosis. 2021."},{"issue":"9","key":"1506_CR74","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1111\/epi.18046","volume":"65","author":"J Sourbron","year":"2024","unstructured":"Sourbron J, et al. Vitamin D prophylaxis in persons with epilepsy? Epilepsia. 2024;65(9):2567\u201379.","journal-title":"Epilepsia"},{"issue":"6","key":"1506_CR75","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1093\/brain\/aws099","volume":"135","author":"MT Wallin","year":"2012","unstructured":"Wallin MT, et al. The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service. Brain. 2012;135(6):1778\u201385.","journal-title":"Brain"},{"issue":"6","key":"1506_CR76","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/1352458516634871","volume":"22","author":"SA Sanai","year":"2016","unstructured":"Sanai SA, et al. Aging and multiple sclerosis. Multiple Scler J. 2016;22(6):717\u201325.","journal-title":"Multiple Scler J"},{"key":"1506_CR77","doi-asserted-by":"publisher","first-page":"554375","DOI":"10.3389\/fneur.2021.554375","volume":"12","author":"R Bove","year":"2021","unstructured":"Bove R, et al. Effects of menopause in women with multiple sclerosis: an evidence-based review. Front Neurol. 2021;12:554375.","journal-title":"Front Neurol"},{"key":"1506_CR78","doi-asserted-by":"publisher","first-page":"812147","DOI":"10.3389\/fneur.2021.812147","volume":"12","author":"L Ross","year":"2022","unstructured":"Ross L, et al. Women\u2019s health in multiple sclerosis: a scoping review. Front Neurol. 2022;12:812147.","journal-title":"Front Neurol"},{"key":"1506_CR79","doi-asserted-by":"publisher","first-page":"1355817","DOI":"10.3389\/fneur.2024.1355817","volume":"15","author":"L Ross","year":"2024","unstructured":"Ross L, et al. Priority setting: women\u2019s health topics in multiple sclerosis. Front Neurol. 2024;15:1355817.","journal-title":"Front Neurol"},{"key":"1506_CR80","first-page":"e200588","volume-title":"Expert Opinion on Age-Related Sex Hormone Changes and Hypogonadism in People With Multiple Sclerosis: A Delphi Consensus Program","author":"R Bove","year":"2026","unstructured":"Bove R, et al. Expert Opinion on Age-Related Sex Hormone Changes and Hypogonadism in People With Multiple Sclerosis: A Delphi Consensus Program. Volume 16. Neurology: Clinical Practice; 2026. p. e200588. 2."},{"issue":"11","key":"1506_CR81","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1001\/jamaneurol.2024.3062","volume":"81","author":"LH Hua","year":"2024","unstructured":"Hua LH, et al. Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations: A Review. JAMA Neurol. 2024;81(11):1210\u201322.","journal-title":"JAMA Neurol"},{"issue":"6","key":"1506_CR82","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1093\/brain\/awh152","volume":"127","author":"S Vukusic","year":"2004","unstructured":"Vukusic S, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain. 2004;127(6):1353\u201360.","journal-title":"Brain"},{"issue":"9","key":"1506_CR83","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/jnnp-2022-330533","volume":"94","author":"C Schubert","year":"2023","unstructured":"Schubert C, et al. Postpartum relapse risk in multiple sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2023;94(9):718\u201325.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"1506_CR84","doi-asserted-by":"publisher","first-page":"103363","DOI":"10.1016\/j.autrev.2023.103363","volume":"22","author":"F Bridge","year":"2023","unstructured":"Bridge F, et al. The impact of menopause on multiple sclerosis. Autoimmun rev. 2023;22(8):103363.","journal-title":"Autoimmun rev"},{"issue":"11","key":"1506_CR85","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1136\/jnnp-2019-320587","volume":"90","author":"D Baroncini","year":"2019","unstructured":"Baroncini D, et al. Impact of natural menopause on multiple sclerosis: a multicentre study. J Neurol Neurosurg Psychiatry. 2019;90(11):1201\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1506_CR86","doi-asserted-by":"publisher","first-page":"108826","DOI":"10.1016\/j.maturitas.2026.108826","volume":"206","author":"D Morgan","year":"2026","unstructured":"Morgan D, et al. Menopause and multiple sclerosis: A scoping review of symptoms, disease course, and lived experience. Maturitas. 2026;206:108826.","journal-title":"Maturitas"},{"issue":"9","key":"1506_CR87","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, et al. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol. 2020;77(9):1132\u201340.","journal-title":"JAMA Neurol"},{"issue":"5","key":"1506_CR88","doi-asserted-by":"publisher","first-page":"e14491","DOI":"10.1111\/acel.14491","volume":"24","author":"M Dema","year":"2025","unstructured":"Dema M, et al. Disease Aggravation With Age in an Experimental Model of Multiple Sclerosis: Role of Immunosenescence. Aging Cell. 2025;24(5):e14491.","journal-title":"Aging Cell"},{"issue":"1","key":"1506_CR89","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(22)00184-3","volume":"22","author":"JS Graves","year":"2023","unstructured":"Graves JS, et al. Ageing and multiple sclerosis. Lancet Neurol. 2023;22(1):66\u201377.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1506_CR90","doi-asserted-by":"publisher","first-page":"e210228","DOI":"10.1212\/WNL.0000000000210228","volume":"104","author":"HE Silverman","year":"2025","unstructured":"Silverman HE, et al. Association of Menopause With Functional Outcomes and Disease Biomarkers in Women With Multiple Sclerosis. Neurology. 2025;104(2):e210228.","journal-title":"Neurology"},{"issue":"7","key":"1506_CR91","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1177\/1352458515606211","volume":"22","author":"R Bove","year":"2016","unstructured":"Bove R, et al. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Multiple Scler J. 2016;22(7):935\u201343.","journal-title":"Multiple Scler J"},{"issue":"3\u20134","key":"1506_CR92","first-page":"223","volume":"80","author":"F Ladeira","year":"2019","unstructured":"Ladeira F, et al. The influence of menopause in multiple sclerosis course: a longitudinal cohort study. Eur Neurol. 2019;80(3\u20134):223\u20137.","journal-title":"Eur Neurol"},{"issue":"1","key":"1506_CR93","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12883-023-03332-1","volume":"23","author":"Z Shahraki","year":"2023","unstructured":"Shahraki Z, et al. Impact of menopause on relapse rate and disability level in patients with multiple sclerosis (MS): a systematic review and meta-analysis. BMC Neurol. 2023;23(1):316.","journal-title":"BMC Neurol"},{"issue":"1","key":"1506_CR94","doi-asserted-by":"publisher","first-page":"e16566","DOI":"10.1111\/ene.16566","volume":"32","author":"CS Simonsen","year":"2025","unstructured":"Simonsen CS, et al. The influence of menopause on multiple sclerosis. Eur J Neurol. 2025;32(1):e16566.","journal-title":"Eur J Neurol"},{"issue":"4","key":"1506_CR95","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/ene.14782","volume":"29","author":"S Otero-Romero","year":"2022","unstructured":"Otero-Romero S, et al. Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset. Eur J Neurol. 2022;29(4):1075\u201381.","journal-title":"Eur J Neurol"},{"issue":"3","key":"1506_CR96","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1212\/WNL.0000000000004843","volume":"90","author":"JS Graves","year":"2018","unstructured":"Graves JS, et al. Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology. 2018;90(3):e254\u201360.","journal-title":"Neurology"},{"key":"1506_CR97","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0079-6123(09)17516-7","volume":"175","author":"SM Gold","year":"2009","unstructured":"Gold SM, Voskuhl RR. Estrogen and testosterone therapies in multiple sclerosis. Prog Brain Res. 2009;175:239\u201351.","journal-title":"Prog Brain Res"},{"issue":"37","key":"1506_CR98","doi-asserted-by":"publisher","first-page":"14813","DOI":"10.1073\/pnas.0703783104","volume":"104","author":"S Tiwari-Woodruff","year":"2007","unstructured":"Tiwari-Woodruff S, et al. Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligand treatment. Proc Natl Acad Sci U S A. 2007;104(37):14813\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1506_CR99","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1177\/0300060517746026","volume":"46","author":"\u00dc T\u00fcrk B\u00f6r\u00fc","year":"2018","unstructured":"T\u00fcrk B\u00f6r\u00fc \u00dc, et al. Effects of multiple sclerosis and medications on menopausal age. J Int Med Res. 2018;46(3):1249\u201353.","journal-title":"J Int Med Res"},{"key":"1506_CR100","doi-asserted-by":"publisher","first-page":"103747","DOI":"10.1016\/j.msard.2022.103747","volume":"61","author":"R Bove","year":"2022","unstructured":"Bove R, et al. A hormonal therapy for menopausal women with MS: A phase Ib\/IIa randomized controlled trial. Multiple Scler Relat disorders. 2022;61:103747.","journal-title":"Multiple Scler Relat disorders"},{"issue":"6","key":"1506_CR101","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1111\/ene.15299","volume":"29","author":"TI Kopp","year":"2022","unstructured":"Kopp TI, Lidegaard \u00d8, Magyari M. Hormone therapy and disease activity in Danish women with multiple sclerosis: a population-based cohort study. Eur J Neurol. 2022;29(6):1753\u201362.","journal-title":"Eur J Neurol"},{"issue":"7","key":"1506_CR102","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1002\/jnr.23019","volume":"90","author":"AJ MacKenzie-Graham","year":"2012","unstructured":"MacKenzie-Graham AJ, et al. Estrogen treatment prevents gray matter atrophy in experimental autoimmune encephalomyelitis. J Neurosci Res. 2012;90(7):1310\u201323.","journal-title":"J Neurosci Res"},{"issue":"11","key":"1506_CR103","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/aje\/kwg068","volume":"157","author":"SK Van Den Eeden","year":"2003","unstructured":"Van Den Eeden SK, et al. Incidence of Parkinson\u2019s disease: variation by age, gender, and race\/ethnicity. Am J Epidemiol. 2003;157(11):1015\u201322.","journal-title":"Am J Epidemiol"},{"issue":"10423","key":"1506_CR104","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","volume":"403","author":"Y Ben-Shlomo","year":"2024","unstructured":"Ben-Shlomo Y, et al. The epidemiology of Parkinson\u2019s disease. Lancet. 2024;403(10423):283\u201392.","journal-title":"Lancet"},{"key":"1506_CR105","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.yfrne.2017.09.002","volume":"50","author":"JC Jurado-Coronel","year":"2018","unstructured":"Jurado-Coronel JC, et al. Sex differences in Parkinson\u2019s disease: Features on clinical symptoms, treatment outcome, sexual hormones and genetics. Front Neuroendocrinol. 2018;50:18\u201330.","journal-title":"Front Neuroendocrinol"},{"issue":"6","key":"1506_CR106","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1007\/s00415-024-12258-8","volume":"271","author":"R Bovenzi","year":"2024","unstructured":"Bovenzi R, et al. A biological characterization of patients with postmenopausal Parkinson\u2019s disease. J Neurol. 2024;271(6):3610\u20135.","journal-title":"J Neurol"},{"issue":"10","key":"1506_CR107","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/mds.28760","volume":"36","author":"CD Kusters","year":"2021","unstructured":"Kusters CD, et al. Increased menopausal age reduces the risk of Parkinson\u2019s disease: a Mendelian randomization approach. Mov Disord. 2021;36(10):2264\u201372.","journal-title":"Mov Disord"},{"issue":"9","key":"1506_CR108","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s10654-020-00672-x","volume":"35","author":"JE Yoo","year":"2020","unstructured":"Yoo JE, et al. Female reproductive factors and the risk of Parkinson\u2019s disease: a nationwide cohort study: JE Yoo et al. Eur J Epidemiol. 2020;35(9):871\u20138.","journal-title":"Eur J Epidemiol"},{"issue":"12","key":"1506_CR109","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.parkreldis.2013.07.020","volume":"19","author":"E Cereda","year":"2013","unstructured":"Cereda E, et al. Reproductive factors and clinical features of Parkinson\u2019s disease. Parkinsonism Relat Disord. 2013;19(12):1094\u20139.","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"1506_CR110","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/mds.28563","volume":"36","author":"M Canonico","year":"2021","unstructured":"Canonico M, et al. Increased risk of Parkinson\u2019s disease in women after bilateral oophorectomy. Mov Disord. 2021;36(7):1696\u2013700.","journal-title":"Mov Disord"},{"issue":"10","key":"1506_CR111","doi-asserted-by":"publisher","first-page":"e2238663","DOI":"10.1001\/jamanetworkopen.2022.38663","volume":"5","author":"WA Rocca","year":"2022","unstructured":"Rocca WA, et al. Association of premenopausal bilateral oophorectomy with parkinsonism and Parkinson disease. JAMA Netw Open. 2022;5(10):e2238663.","journal-title":"JAMA Netw Open"},{"key":"1506_CR112","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bbr.2017.07.025","volume":"335","author":"M Lv","year":"2017","unstructured":"Lv M, et al. Reproductive factors and risk of Parkinson\u2019s disease in women: A meta-analysis of observational studies. Behav Brain Res. 2017;335:103\u201310.","journal-title":"Behav Brain Res"},{"issue":"6","key":"1506_CR113","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1093\/brain\/awac440","volume":"146","author":"G Pesce","year":"2023","unstructured":"Pesce G, et al. Reproductive characteristics, use of exogenous hormones and Parkinson disease in women from the E3N study. Brain. 2023;146(6):2535\u201346.","journal-title":"Brain"},{"issue":"10","key":"1506_CR114","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.parkreldis.2011.07.007","volume":"17","author":"Parkinson Study Group POETRY Investigators","year":"2011","unstructured":"Parkinson Study Group POETRY Investigators. A randomized pilot trial of estrogen replacement therapy in post-menopausal women with Parkinson's disease. Parkinsonism Relat Disord. 2011;17(10):757\u201360. https:\/\/doi.org\/10.1016\/j.parkreldis.2011.07.007","journal-title":"Parkinsonism Relat Disord"},{"key":"1506_CR115","doi-asserted-by":"publisher","unstructured":"Tsang KL, Ho SL, Lo SK. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology. 2000;54(12):2292-8. PMID: 10881255 https:\/\/doi.org\/10.1212\/wnl.54.12.2292","DOI":"10.1212\/wnl.54.12.2292"},{"issue":"2","key":"1506_CR116","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/00002826-199903000-00005","volume":"22","author":"E Strijks","year":"1999","unstructured":"Strijks E, Kremer JA, Horstink MW. Effects of female sex steroids on Parkinson\u2019s disease in postmenopausal women. Clin Neuropharmacol. 1999;22(2):93\u20137.","journal-title":"Clin Neuropharmacol"},{"key":"1506_CR117","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3389\/fnins.2020.00157","volume":"14","author":"Y-j Song","year":"2020","unstructured":"Song Y-j, et al. The effect of estrogen replacement therapy on Alzheimer\u2019s disease and Parkinson\u2019s disease in postmenopausal women: a meta-analysis. Front NeuroSci. 2020;14:157.","journal-title":"Front NeuroSci"},{"issue":"4","key":"1506_CR118","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.parkreldis.2013.01.008","volume":"19","author":"K Rugbjerg","year":"2013","unstructured":"Rugbjerg K, et al. Exposure to estrogen and women\u2019s risk for Parkinson\u2019s disease: a prospective cohort study in Denmark. Parkinsonism Relat Disord. 2013;19(4):457\u201360.","journal-title":"Parkinsonism Relat Disord"},{"key":"1506_CR119","doi-asserted-by":"crossref","unstructured":"Association As. 2019 Alzheimer\u2019s disease facts and figures. Volume 15. Alzheimer\u2019s & dementia; 2019. pp. 321\u201387. 3.","DOI":"10.1016\/j.jalz.2019.01.010"},{"issue":"9","key":"1506_CR120","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.jalz.2018.04.008","volume":"14","author":"RA Nebel","year":"2018","unstructured":"Nebel RA, et al. Understanding the impact of sex and gender in Alzheimer\u2019s disease: A call to action. Alzheimers Dement. 2018;14(9):1171\u201383.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"1506_CR121","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaneurol.2017.2188","volume":"74","author":"SC Neu","year":"2017","unstructured":"Neu SC, et al. Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. JAMA Neurol. 2017;74(10):1178\u201389.","journal-title":"JAMA Neurol"},{"key":"1506_CR122","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jsbmb.2016.03.012","volume":"160","author":"BC Riedel","year":"2016","unstructured":"Riedel BC, Thompson PM, Brinton RD. Age, APOE and sex: Triad of risk of Alzheimer\u2019s disease. J Steroid Biochem Mol Biol. 2016;160:134\u201347.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"1506_CR123","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jamaneurol.2025.0013","volume":"82","author":"GT Coughlan","year":"2025","unstructured":"Coughlan GT, et al. Sex Differences in Longitudinal Tau-PET in Preclinical Alzheimer Disease: A Meta-Analysis. JAMA Neurol. 2025;82(4):364\u201375.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1506_CR124","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/jamaneurol.2025.5670","volume":"83","author":"GT Coughlan","year":"2026","unstructured":"Coughlan GT, et al. Sex Differences in P-Tau217, Tau Aggregation, and Cognitive Decline. JAMA Neurol. 2026;83(4):369\u201381.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1506_CR125","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck CH, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"key":"1506_CR126","doi-asserted-by":"crossref","unstructured":"Teipel SJ, Tang Y, Khachaturian A. Sex differences in treatment effects of lecanemab and donanemab: A Bayesian reanalysis of CLARITY-AD and TRAILBLAZER-ALZ2. Volume 11. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions,; 2025. p. e70155. 3.","DOI":"10.1002\/trc2.70155"},{"issue":"1","key":"1506_CR127","doi-asserted-by":"publisher","first-page":"e14467","DOI":"10.1002\/alz.14467","volume":"21","author":"D Andrews","year":"2025","unstructured":"Andrews D, et al. The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect. Alzheimers Dement. 2025;21(1):e14467.","journal-title":"Alzheimers Dement"},{"key":"1506_CR128","doi-asserted-by":"publisher","first-page":"150226","DOI":"10.1016\/j.brainres.2026.150226","volume":"1879","author":"M Manasa","year":"2026","unstructured":"Manasa M, et al. Harnessing estrogen\u2019s neuroprotective potential in mitigating Alzheimer\u2019s pathologies in postmenopausal women: a review. Brain Res. 2026;1879:150226.","journal-title":"Brain Res"},{"issue":"4","key":"1506_CR129","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s11010-024-05071-4","volume":"480","author":"X Wang","year":"2025","unstructured":"Wang X, et al. The role of estrogen in Alzheimer\u2019s disease pathogenesis and therapeutic potential in women. Mol Cell Biochem. 2025;480(4):1983\u201398.","journal-title":"Mol Cell Biochem"},{"issue":"13","key":"1506_CR130","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1212\/WNL.0000000000004425","volume":"89","author":"L Mosconi","year":"2017","unstructured":"Mosconi L, et al. Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging. Neurology. 2017;89(13):1382\u201390.","journal-title":"Neurology"},{"issue":"1","key":"1506_CR131","doi-asserted-by":"publisher","first-page":"11546","DOI":"10.1038\/s41467-025-66726-4","volume":"16","author":"JK Sun","year":"2025","unstructured":"Sun JK, et al. Perimenopausal state oestradiol to progesterone imbalance drives Alzheimer\u2019s risk via ERR\u03b1 dysregulation and energy dyshomeostasis. Nat Commun. 2025;16(1):11546.","journal-title":"Nat Commun"},{"issue":"12","key":"1506_CR132","doi-asserted-by":"publisher","first-page":"e0207885","DOI":"10.1371\/journal.pone.0207885","volume":"13","author":"L Mosconi","year":"2018","unstructured":"Mosconi L, et al. Increased Alzheimer\u2019s risk during the menopause transition: a 3-year longitudinal brain imaging study. PLoS ONE. 2018;13(12):e0207885.","journal-title":"PLoS ONE"},{"issue":"1","key":"1506_CR133","doi-asserted-by":"publisher","first-page":"10867","DOI":"10.1038\/s41598-021-90084-y","volume":"11","author":"L Mosconi","year":"2021","unstructured":"Mosconi L, et al. Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition. Sci Rep. 2021;11(1):10867.","journal-title":"Sci Rep"},{"issue":"9","key":"1506_CR134","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/humrep\/dead130","volume":"38","author":"W Hao","year":"2023","unstructured":"Hao W, et al. Age at menopause and all-cause and cause-specific dementia: a prospective analysis of the UK Biobank cohort. Hum Reprod. 2023;38(9):1746\u201354.","journal-title":"Hum Reprod"},{"key":"1506_CR135","doi-asserted-by":"publisher","first-page":"107792","DOI":"10.1016\/j.maturitas.2023.107792","volume":"176","author":"EK Karamitrou","year":"2023","unstructured":"Karamitrou EK, et al. Early menopause and premature ovarian insufficiency are associated with increased risk of dementia: a systematic review and meta-analysis of observational studies. Maturitas. 2023;176:107792.","journal-title":"Maturitas"},{"issue":"1","key":"1506_CR136","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3233\/JAD-240646","volume":"102","author":"N Calvo","year":"2024","unstructured":"Calvo N, et al. Associated risk and resilience factors of Alzheimer\u2019s disease in women with early bilateral oophorectomy: Data from the UK Biobank. J Alzheimers Dis. 2024;102(1):119\u201328.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1506_CR137","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000314681","volume":"30","author":"TKT Phung","year":"2010","unstructured":"Phung TKT, et al. Hysterectomy, Oophorectomy and Risk of Dementia: A Nationwide Historical Cohort Study. Dement Geriatr Cogn Disord. 2010;30(1):43\u201350.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"11","key":"1506_CR138","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1212\/01.wnl.0000276984.19542.e6","volume":"69","author":"W Rocca","year":"2007","unstructured":"Rocca W, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69(11):1074\u201383.","journal-title":"Neurology"},{"issue":"5","key":"1506_CR139","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1097\/AOG.0000000000002044","volume":"129","author":"Committee","year":"2017","unstructured":"Committee. Opinion 698: Hormone Therapy in Primary Ovarian Insufficiency. Obstet Gynecol, 2017. 129(5): pp. e134\u201341.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"1506_CR140","doi-asserted-by":"publisher","first-page":"hoae065","DOI":"10.1093\/hropen\/hoae065","volume":"2024","author":"N Panay","year":"2024","unstructured":"Panay N, et al. Evidence-based guideline: premature ovarian insufficiency. Hum Reprod open. 2024;2024(4):hoae065.","journal-title":"Hum Reprod open"},{"issue":"20","key":"1506_CR141","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1001\/jama.289.20.2651","volume":"289","author":"SA Shumaker","year":"2003","unstructured":"Shumaker SA, et al. Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal WomenThe Women\u2019s Health Initiative Memory Study: A Randomized Controlled Trial. JAMA. 2003;289(20):2651\u201362.","journal-title":"JAMA"},{"issue":"6","key":"1506_CR142","doi-asserted-by":"publisher","first-page":"pe1001833","DOI":"10.1371\/journal.pmed.1001833","volume":"12","author":"CE Gleason","year":"2015","unstructured":"Gleason CE, et al. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study. PLoS Med. 2015;12(6):pe1001833\u2013discussione1001833.","journal-title":"PLoS Med"},{"issue":"11","key":"1506_CR143","doi-asserted-by":"publisher","first-page":"e1004435","DOI":"10.1371\/journal.pmed.1004435","volume":"21","author":"CE Gleason","year":"2024","unstructured":"Gleason CE, et al. Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study. PLoS Med. 2024;21(11):e1004435.","journal-title":"PLoS Med"},{"key":"1506_CR144","doi-asserted-by":"publisher","first-page":"1260427","DOI":"10.3389\/fnagi.2023.1260427","volume":"15","author":"M Nerattini","year":"2023","unstructured":"Nerattini M, et al. Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer\u2019s disease and dementia. Front Aging Neurosci. 2023;15:1260427.","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"1506_CR145","doi-asserted-by":"publisher","first-page":"103554","DOI":"10.1016\/j.jpet.2025.103554","volume":"392","author":"Q Song","year":"2025","unstructured":"Song Q, et al. Association between duration, initiation time, routes, and formulations of menopausal hormone therapy use and Alzheimer disease in women: A systematic review and meta-analysis. J Pharmacol Exp Ther. 2025;392(5):103554.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"1506_CR146","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.tins.2008.07.003","volume":"31","author":"RD Brinton","year":"2008","unstructured":"Brinton RD. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci. 2008;31(10):529\u201337.","journal-title":"Trends Neurosci"},{"issue":"17","key":"1506_CR147","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1001\/jama.2022.18324","volume":"328","author":"G Gartlehner","year":"2022","unstructured":"Gartlehner G, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022;328(17):1747\u201366.","journal-title":"JAMA"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-026-01506-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-026-01506-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-026-01506-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:02:39Z","timestamp":1784887359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-026-01506-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":147,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1506"],"URL":"https:\/\/doi.org\/10.1007\/s11910-026-01506-1","relation":{},"ISSN":["1534-6293"],"issn-type":[{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"19 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal or human subjects were used by the authors in this study.","order":3,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"37"}}